Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.

COMPLETED NA

The Efficacy of a Frequency-tuned Electromagnetic Field Treatment in Facilitating the Recovery of Subacute Ischemic Stroke Patients - a Pivotal Study (THE "EMAGINE" STUDY)

NCT05044507 · View on ClinicalTrials.gov ↗

Study Summary

This is a multicenter study that will be conducted at approximately 20 centers. BQ 2.0 is a wearable medical device that produces and delivers non-invasive, extremely-low-intensity and low-frequency, frequency-tuned electromagnetic fields in order to stimulate neuronal networks with the aim of reducing disability and promoting neurorecovery. In this study, BQ 2.0 is intended to reduce disability in adult patients with subacute ischemic stroke, with a moderate to severe disability which includes an upper extremity motor impairment. BQ 2.0 will be used for 9 weeks in conjunction with physical and occupational therapy (PT/OT) and periodic supervision (either remote or in person) of a trained site study team member. Treatments may be administered in multiple settings (e.g. acute care hospital (ACH) or inpatient rehabilitation facilities (IRF), Skilled Nursing Facility (SNF), home or other outpatient setup). The study will enroll up to 150 adult subjects who will be randomly assigned (1:1 allocation ratio) to either active or sham study intervention using BQ 2.0.

Conditions Studied

Interventions

  • DEVICE BQ 2.0

Study Locations (15)

California

  • Rancho Research Institute — Downey
  • Ronald Reagan UCLA Medical Center & California Rehabilitation Institute — Los Angeles

Florida

  • Brooks Rehabilitation Hospital - University Campus — Jacksonville
  • The Miami Project to Cure Paralysis — Miami

New Jersey

  • JFK Johnson Rehabilitation Institute — Edison
  • Kessler Institute of Rehabilitation — West Orange

Texas

  • Baylor Scott & White Institute for Rehabilitation — Dallas
  • TIRR Memorial Hermann Hospital — Houston

District of Columbia

  • MedStar National Rehabililtaion Hospital, — Washington D.C.

Illinois

  • Shirley Ryan Abilitylab — Chicago

Kansas

  • KU Medical Center — Kansas City

Massachusetts

  • Spaulding Rehabilitation Hospital — Boston

Trial Details

FieldValue
Enrollment Target 100 participants
Start Date 2021-12-04
Est. Completion 2024-01-16
Phase NA

Sponsor

BrainQ Technologies

2 total trials

Interested in This Trial?

Always speak with your doctor before enrolling in a clinical trial.

Full Details on ClinicalTrials.gov ↗

What the Registry Record Tells You About NCT05044507

The ClinicalTrials.gov registry entry for NCT05044507 describes a study currently listed as completed. It is categorized as NA, which is the standard way researchers label where a study sits along the investigational pathway from early safety work through later efficacy and post-marketing evaluation. The registered enrollment target is 100 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is BrainQ Technologies, which has 2 total studies on file at ClinicalTrials.gov, and sponsors are the parties responsible for study design, oversight, and regulatory filings.

The record links to 1 condition, with Ischemic Stroke appearing as the primary indexed condition, and to 1 intervention — of which BQ 2.0 is the first listed. Interventions can include drugs, devices, procedures, behavioral programs, or observational arms, and each is tracked as a separate registry field so that downstream queries can filter accurately. When a trial lists multiple interventions, it usually reflects a multi-arm design or a comparison protocol rather than a single treatment being tested in isolation. The brief summary published in the registry is the clearest source of protocol intent and should be read before drawing conclusions from any sidebar tags.

Geographic footprint matters for practical reasons: NCT05044507 reports 15 study locations spanning 11 distinct geographic areas — top geographies include California, Florida, New Jersey. A larger site network tends to correlate with broader recruitment capacity, but it does not imply anything about study quality, and site-level enrollment status can diverge from the overall registry status shown above. Every data point on this page comes from the public ClinicalTrials.gov dataset and is reproduced here for reference only; it is not a medical recommendation, an endorsement of the sponsor, or an invitation to enroll. Verify current status, eligibility criteria, and contact details directly at ClinicalTrials.gov, and discuss any participation decision with your own healthcare provider.

Frequently Asked Questions

What is clinical trial NCT05044507 about?

NCT05044507 is a clinical study titled "The Efficacy of a Frequency-tuned Electromagnetic Field Treatment in Facilitating the Recovery of Subacute Ischemic Stroke Patients - a Pivotal Study (THE "EMAGINE" STUDY)". This is a multicenter study that will be conducted at approximately 20 centers. BQ 2.0 is a wearable medical device that produces and delivers non-invasive, extremely-low-intensity and low-frequency, frequency-tuned electromagnetic fields in order to stimulate neuronal networks with the aim of reduc...

What is the current status of trial NCT05044507?

This trial is currently completed. It is a NA study. The enrollment target is 100 participants. The study started on 2021-12-04. Estimated completion is 2024-01-16.

What conditions does trial NCT05044507 study?

This clinical trial studies the following conditions: Ischemic Stroke. These conditions were identified from the trial registry and reflect the primary focus areas of the research.

What interventions are being tested in trial NCT05044507?

The interventions under investigation include: BQ 2.0 (DEVICE). Each intervention is being evaluated for safety and efficacy as part of this clinical study.

Who is sponsoring clinical trial NCT05044507?

This trial is sponsored by BrainQ Technologies, which has 2 total clinical trials registered on ClinicalTrials.gov. The sponsor is responsible for the study's design, funding, and regulatory compliance.

Where is trial NCT05044507 being conducted?

This trial has 15 study locations across California, District of Columbia, Florida, Illinois, Kansas. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.

Related

Data sourced from official U.S. government datasets. See our methodology for details. Retrieved and formatted by PlainTrial Editorial